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Abstract Purpose: Camptothecin (CPT) has potent broad-spectrum antitumor activity by inhibit-
ing type I DNA topoisomerase (DNA topo I). It has not been used clinically because it is
water-insoluble and highly toxic. As a result, irinotecan (CPT-11), a water-soluble ana-
logue of CPT, has been developed and used as salvage chemotherapy in patients with
relapsed/refractory lymphoma, but with only modest activity. Recently, we have devel-
oped a cyclodextrin-based polymer conjugate of 20-(S)-CPT (IT-101). In this study, we
evaluated the preclinical antilymphoma efficacy of IT-101 as compared with CPT-11.
Experimental Design: We determined an in vitro cytotoxicity of IT-101, CPT-11, and
their metabolites against multiple human lymphoma cell lines. In human lymphoma
xenografts, the pharmacokinetics, inhibitions of tumor DNA topo I catalytic activity,
and antilymphoma activities of these compounds were evaluated.
Results: IT-101 and CPT had very high in vitro cytotoxicity against all lymphoma cell
lines tested. As compared with CPT-11 and SN-38, IT-101 and CPT had longer release
kinetics and significantly inhibit higher tumor DNA topo I catalytic activities. Further-
more, IT-101 showed significantly prolonged the survival of animals bearing s.c. and
disseminated human xenografts when compared with CPT-11 at its maximum tolerated
dose in mice.
Conclusions: The promising present results provide the basis for a phase I clinical trial
in patients with relapsed/refractory lymphoma.
Although great advances have been made in the treatment of
malignant lymphoma, more than half of the patients with ag-
gressive non-Hodgkin lymphoma and a vast majority of pa-
tients with indolent lymphoma have resistant diseases or
relapse after the initial treatment and eventually require salvage
chemotherapy. In general, patients with Burkitt lymphoma, an-
aplastic large T-cell lymphoma, and advanced-stage Hodgkin
lymphoma who receive first-line combination chemotherapies
can achieve 5-year overall survival rate of 65% to 90%, 37% to
93%, and 66% to 82% of patients, respectively (1–5). However,
only a small number of these patients can achieve long-term
disease-free survival after high-dose therapy and hematopoietic
stem cell rescue. The limitation of this approach is that not all
patients respond to widely used salvage therapies including EP-
OCH (6), ESHAP (7), and MINE-ESHAP (8). Therefore, a novel
agent for the salvage setting in these patients is needed. The de-
velopment of salvage regimens is based on the combination of
non–cross-resistant agents from the first-line chemotherapy re-
gimens. The DNA topoisomerase I (Topo I) inhibitors have
been explored as candidates for salvage therapy in patients with
relapsed/refractory non-Hodgkin lymphoma due to an increase
of DNA Topo I activity in lymphoma cells. 20(S)-Camptothecin
(CPT) is a plant alkaloid present in fruit, bark, and wood of the
Camptotheca acuminata. CPT has a broad spectrum of antitumor
activity that mediates through interaction with the nuclear en-
zyme Topo I and prevents it from resealing the DNA break, re-
sulting in a double-strain DNA break and cell death (9–12).
Moreover, it is a poor substrate for P-glycoprotein, a class of
drug efflux pumps that is up-regulated in many multidrug resis-
tant cancer cells. However, the clinical use of CPT has been pre-
cluded by its significant treatment-related toxicity (TRT) and
low antitumor efficacy (13, 14). Irinotecan (CPT-11), an ana-
logue of CPT, has been used alone or in combination with
other cytotoxic agents as salvage regimen for patients with
relapsed/refractory non-Hodgkin lymphoma (15–18). In spite
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of the high response shown in the phase II study of CPT-11
against a broad range of solid tumors, it usually has not been
employed in the treatment of malignant lymphoma. This is
mainly because of its common TRT including grade 3/4 leukope-
nia and grade 3/4 diarrhea caused by the recommended dosing
schedule of this agent (16–19). Although prolonged i.v. infusion
of CPT-11 has been reported to enhance antitumor activity (20,
21), a disadvantage of this delivery method observed in xeno-
graft models and early clinical trials was again a high incidence
of TRT including diarrhea, nausea/vomiting, neutropenia, ane-
mia, and pulmonary toxicity (22–25). IT-101, a nanoparticulate
conjugate of 20(S)-camptothecin and a β-cyclodextrin-based
polymer, has recently been developed to improve biodistribu-
tion to tumor tissue, minimize TRT, and increase antitumor ac-
tivity (26, 27). In a preclinical study, IT-101 has been able to
show antitumor activity against a broad range of solid tumors
(28). Therefore, we carried out this study to determine the pre-
clinical efficacy of this novel compound in human lymphoma
xenografts.
Materials and Methods
DNA construct. The bifunctional ffLuc:Zeocin fusion gene that coex-
presses the firefly luciferase (ffLuc) and zeocin (Zeo) resistance genes
was cloned into pcDNA3.1+ (Invitrogen) to generate plasmid ffLuc:
Zeocin-pcDNA3.1+ as previously described (29).
Cell culture and genetic modification. Daudi cell (human Burkitt
lymphoma line) was obtained from the American Type Culture Collec-
tion. Karpas 299 cell (human anaplastic large T-cell lymphoma line)
was obtained from Deutsche Sammlung von Mikroorganism und Zellk-
ulturen GmbH. L540 cell (human Hodgkin lymphoma line) was kindly
provided by Dr. Andreas Engert (University Clinic of Cologne, Cologne,
Germany). These cell lines were maintained in sterile culture media as
previously described (29). Daudi and Karpas cells (8 × 106) were genet-
ically modified with 10 μg of ffLuc:Zeocin-pcDNA3.1+ linearized DNA
plasmid as previously described (29). Beginning on the third day after
electrotransfer, zeocin (InvivoGen) was added to the culture at a con-
centration of 0.1 to 0.4 mg/mL to maintain stable transfection.
In vitro cytotoxicity of IT-101 against human lymphoma cell lines.
The toxicities of CPT, IT-101, SN-38 (active metabolite of CPT-11),
and CPT-11 were determined in Daudi, Karpas 299, and L540 cells after
72 h of incubation in RPMI 1640 supplemented with 10% heat-
inactivated fetal bovine serum (Daudi cell and Karpas cell) or 20% fetal
bovine serum (L540 cell) using the MTS assay.
Human lymphoma xenograft models. Mouse care and experimental
procedures were carried out in accordance with the Research Animal
Care Committee (RACC) of Beckman Research Institute at City of Hope.
We first established three localized s.c. models in 6- to 8-week-old fe-
male severe combined immunodeficiency (SCID/NCr, BALB/C back-
ground) mice (National Cancer Institute). These animals were
injected with 0.2 mL of 1:1 mixture of tumor cell suspension in 1% hu-
man serum albumin in HBSS (Mediatech) and Matrigel (BD Bios-
ciences) into their right flanks. The cell dose of Daudi cell, Karpas
299 cell, and L540 cell was 5 × 106, 3 × 106, and 5 × 106 cells, respec-
tively. To establish two disseminated models, 6- to 8-week-old female
nonobese diabetic severe combined immunodeficiency (NOD.scid/
NCr) mice (National Cancer Institute) were injected with 0.2 mL of
1:1 lymphoma cells stably expressing ffLuc activity in a suspension of
1× Dulbecco's PBS solution (Mediatech) and 1% heat-inactivated fetal
bovine serum via lateral tail vein. The cell doses of Daudi cell and
Karpas 299 cell were 7.5 × 106 and 5 × 106 cells, respectively.
Plasma and tumor concentrations of IT-101, CPT, CPT-11, and SN-38.
Localized s.c. human xenograft–bearing animals with tumor volumes
reaching approximately 500 to 800 mm3 were randomly divided into
two treatment groups of 20 animals each: group 1 on CPT-11
(100 mg/kg, i.p., single dose) and group 2 on IT-101 (10 mg/kg, i.v.,
single dose). Then tumor specimens and plasma from five mice in each
treatment group were corrected at four time points (before dosing, and
2, 24, and 48 h after dosing) to measure plasma and tumor concentra-
tions of the compounds and their active metabolites. Measurements of
plasma and tumor concentrations of IT-101 and CPT were carried out
for SCID mice treated with IT-101, whereas those of CPT-11 and SN-38
were carried out for mice treated with CPT-11. The method of these
measurements has been previously described (26).
Tumor type I DNA Topo I catalytic activity inhibited by IT-101 and
CPT-11. At each time point along with the measurements of plasma
and tumor concentrations of IT-101, CPT-11, and their metabolites,
the inhibition of tumor DNA Topo I catalytic activity after administra-
tion of either IT-101 or CPT-11 was evaluated. The catalytic activity of
DNA Topo I was determined by measuring the relaxation of super-
coiled (form I) plasmid substrate DNA using the Topo I assay kit
(TopoGEN) essentially according to the method of Liu and Miller (30).
First, preparation of crude extracts from tumor tissues was done as
previously described (31). Second, nuclear extraction was done using
celLytic nuclear extraction kit (Sigma-Aldrich). Then tumor DNA Topo
I catalytic activity was determined following the instructions accompa-
nying the Topo I assay kit. Briefly, the reaction mixtures used consisted
of supercoiled (form I) plasmid substrate DNA (0.5 μg), tumor nucle-
ar extract (0.5 μg total protein), and the assay buffer. Supercoiled
(form I) plasmid DNA (0.5 μg) and relaxed DNA (0.5 μg) provided
by the Topo I assay kit were used as the control markers. The reaction
mixtures were incubated at 37°C for 30 min, and terminated by add-
ing 5 μL stop buffer/gel loading buffer. Samples were loaded onto a
1% agarose gel submersed in 1× Tris-acetate-EDTA (TAE) buffer (50×
TAE buffer: 242 g Tris base, 57.1 mL glacial acetic acid, and 100 mL
0.5 mol/L EDTA) and electrophoresed overnight at room temperature.
The gel was stained with 0.2 μg/mL ethidium bromide for 20 min at
Translational Relevance
Topoisomerase inhibitors have a broad spectrum
of activity against human cancers including malig-
nant lymphoma. Although camptothecin (CPT), a
type 1 DNA topoisomerase inhibitor, has significant
antitumor activity, its water insolubility and toxicity
has precluded its clinical use, and derivatives such
as irinotecan have been used clinically with some ac-
tivity. We have tested the efficacy of IT-101, which
comprises a cyclodextrin-containing polymer conju-
gate of CPT that self assembles into a nanoparticle of
~30-nm diameter. The drug was designed to reduce
the toxicity of CPT and relies on intracellular chemis-
try to liberate the drug from the protective polymer
once inside the cell. When tested in five different an-
imal models of lymphoma, the drug showed prolon-
gation of survival and the achievement of a complete
remission inmost of the animals comparedwith irino-
tecan, without increased toxicity. As a result, it is our
plan to initiate a phase I/II clinical trial in a broad group
of patients with relapsed/refractory lymphoma.
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room temperature, destained in water for 20 min, and imaged under
UV light. The background of supercoiled DNA band was subtracted,
and the density of the supercoiled DNA band was quantified using
FluorChem AlphaEaseFC2 software (Alpha Innotech). The percentage
of DNA Topo I catalytic activity inhibited by either IT-101 or CPT-11
was equal to the density of supercoiled DNA band from treated tumor
divided by the density of supercoiled DNA band from untreated con-
trol and timed by 100.
Tumor burden monitoring. In the s.c. model, detection of tumor
growth by serial physical measurements was initiated 2 to 7 d after tu-
mor implant and repeated at least twice a week until the average tumor
volume was approximately 100 to 200 mm3 at which the therapy was
initiated. This was repeated at least once a week until the end of the
study. The tumor volume was calculated as previously described (28).
In disseminated model, in vivo biophotonic imaging (see below) was
initiated approximately 7 d after tumor injection.
Biophotonic imaging. The in vivo ffLuc-derived bioluminescent imag-
ing (BLI) signal was evaluated using an IVIS 100 imaging system (Xeno-
gen) at 18 min after a single i.p. injection of dissolved D-Luciferin
(Xenogen) at a dose of 50 mg/kg (0.1 mL of a 10 mg/mL solution
per 20-g mouse). Photons were quantified using the Living Image ver-
sion 2.5 software (Xenogen). Background bioluminescence signal was
defined as <106 p/s/cm2/sr based on the average ffLuc-derived BLI of
normal control mice.
Determination of treatment efficacy. The treatment result for each
animal may be pathologic complete tumor response, complete tumor
response, or partial tumor response. In a complete tumor response,
the tumor volume is <13.5 mm3 for two consecutive measurements
in localized s.c. model, whereas the BLI is <106 p/s/cm2/sr for two
consecutive measurements in the disseminated model. A pathologic
complete tumor response is defined as complete tumor response
combined with evidence of nonviable tumor on histopathologic
study. In a partial tumor response, the tumor volume is <50% of
its pretreatment volume for two consecutive measurements and the
tumor volume ≥13.5 mm3 for one or more of these two measure-
ments, whereas the BLI is <50% of its pretreatment signal and the
BLI signal >106 p/s/cm2/sr for one or both of these two measure-
ments. In accordance with the institutional RACC, the predetermined
tumor end point is defined as follows: (a) tumor volume >2,000 mm3
and/or ulcerated tumor in localized s.c. model; and (b) BLI signal
>1010 p/s/cm2/sr and/or weight loss >20% with evidence of progres-
sive disease and/or hind limb paralysis and/or death from tumor
progression in disseminated model. Percent animal survival is de-
fined by the percentage of animals that did not die of the tumor
or TRT or reach the predetermined tumor end point during the
course of the study. At the end of the study, all survived animals
were euthanized with CO2. In order to detect some residual tumors
by histopathologic study, a whole thickness of skin around the tumor
injection site with or without gross tumor was harvested from ani-
mals with s.c. xenografts; whereas a brain, a heart, a spleen, a liver,
ovaries, kidneys, lungs, femurs, and spines were harvested from ani-
mals with disseminated xenografts.
Treatment schedule and tumor burden monitoring. For reference pur-
poses, CPT-11 was used as the internal positive control in the current
study as previously described (28). Mice with established human lym-
phoma xenografts were allocated into five different treatment groups of
nine animals each, as follows: group 1 (untreated control); group 2
(CPT-11 at 100 mg/kg, i.p., qwk × 3); group 3 (IT-101 at 5 mg/kg,
i.v., qwk × 3); group 4 (IT-101 at 10 mg/kg, i.v., qwk × 3); and group
5 (single dose of IT-101 at 15 mg/kg, i.v.).
Table 1. IC50 of CPT, IT-101, SN-38, and CPT-11 in various lymphoma cell lines after a 72-h incubation period
Lymphoma cell line CPT (μmol/L) IT-101 (μmol/L) SN-38 (μmol/L) CPT-11 (μmol/L)
Daudi 0.06 0.17 0.003 62
Karpas 299 0.02 0.4 0.008 11
L540 0.01 0.06 0.008 2
Fig. 1. A, plasma concentration of
polymer-bound (▪), free CPT (▴), CPT-11 (▾), and SN-38 (♦) as a function oftime after a single bolus i.v. injection of
IT-101 (10 mg/kg) and a single i.p.
injection of CP-11 (100 mg/kg). B, tumor
concentration of polymer-bound (▪),free CPT (▴), CPT-11 (▾), and SN-38 (♦)as a function of time after a single bolus
i.v. injection of IT-101 (10 mg/kg) and
a single i.p. injection of CPT-11
(100 mg/kg). Points, mean; error
bars, SE.
4367 Clin Cancer Res 2009;15(13) July 1, 2009www.aacrjournals.org
IT-101 in Multiple Lymphoma Xenografts
Tumor burdens were monitored at least once weekly toward the
predetermined end points or for 126 d postadministration in the lo-
calized s.c. models and for 90 d postadministration in the disseminat-
ed models.
Tolerability. Mice were weighed twice weekly during treatment and
then weekly until the end of the study and were observed for some ex-
pected TRT, including progressive weight loss, anorexia, and diarrhea.
The unacceptable TRT for the maximum tolerated dose (MTD) was
defined as previously described (28).
Statistical and graphical analyses. For DNA Topo I catalytic activity,
samples were compared by paired t-test. The survival curves were con-
structed using the Kaplan-Meier method. The log-rank test was used
to compare the percent animal survival between treatment groups.
P < 0.05 was considered statistically significant.
Results
In vitro cytotoxicity of Topo I inhibitors against three lymphoma
cell lines. Based on the Developmental Therapeutics Program of
the National Cancer Institute/NIH and our unpublished data,
the IC50 of CPT, IT-101, SN-38, and CPT-11 for colon, breast,
and prostate cancer cell lines were 0.02 to 0.2 μmol/L, 0.22 to
0.38 μmol/L, 0.001 to 0.003 μmol/L, and 13 to 45 μmol/L,
respectively. Using MTS assay, the IC50 ranged from 0.01 to
0.06 μmol/L and 0.06 to 0.4 μmol/L after 72 hours of incuba-
tion with CPT and IT-101, respectively, indicating that both
CPT and IT-101 had very high in vitro cytotoxicity against all
lymphoma cell lines tested (Table 1).
Longer release kinetics of IT-101 and CPT as compared with
CPT-11 and SN-38. In plasma, the maximum concentration
of polymer-bound CPT, free CPT, CPT-11, and SN-38 was at
2 hours posttreatment in all s.c. tumor xenograft animals tested,
but the concentration of CPT-11 and SN-38 declined rapidly at
24 hours posttreatment (Fig. 1A). In the s.c. tumor xenografts
themselves, the maximum concentration of polymer-bound
CPT and free CPT was at 48, 24, and 48 hours posttreatment
in Daudi, Karpas 299, and L540 tumors, respectively, whereas
the maximum concentration of SN-38 was at 2, 2, and 24 hours
posttreatment in Daudi tumors, Karpas 299 tumors, and
L540 tumors, respectively (Fig. 1B). These results indicated
that IT-101 has longer release kinetics in tumor than that of
CPT-11.
Tumor type I DNA Topoisomerase catalytic activity inhibited by
IT-101 and CPT-11. Based on the IT-101 kinetic data above, we
predicted that IT-101 would be able to inhibit tumor DNA
Topo I catalytic activity for a longer time than CPT-11. The sen-
sitivity of tumor cells to either IT-101 or CPT-11 was deter-
mined by inhibition of tumor nuclear Topo I catalytic activity
using a DNA relaxation assay. At 2, 24, and 48 hours posttreat-
ment, both IT-101 (10 mg/kg, i.v., × 1) and CPT-11 (100 mg/kg,
i.p., × 1) could significantly inhibit nuclear DNA Topo I cata-
lytic activity in all types of s.c. lymphoma xenografts tested. At
the 48-h time point, however, IT-101 could inhibit nuclear
DNA Topo I catalytic activity significantly better than CPT-11
in s.c. Daudi tumors and s.c. Karpas 299 tumors (P = 0.007;
95% confidence interval, 11.2-30.99 and P = 0.037; 95% confi-
dence interval, 2.98-48.08, respectively); although there was on-
ly a nonsignificant trend in s.c. L540 tumors (P = 0.07). These
observations are associated with longer release kinetics of IT-
101 in tumor and are consistent with the maximum concentra-
tion of polymer-bound CPT and free CPT at 48 hours posttreat-
ment as compared with SN-38 at 2 hours posttreatment (Fig. 2).
Tolerability. Recent studies have shown that at the same accu-
mulative dose, IT-101 qwk × 3 can simultaneously maximize
antitumor effect and minimize TRT when compared with multi-
ple daily dosing schedules (28). The MTD of IT-101 in solid tu-
mor bearing athymic nudemice (no data in SCID andNOD.scid/
NCr mice) was >16.1 mg/kg qwk × 3 but <25 mg/kg qwk × 3.
However, based on our internal study of human lymphoma xe-
nografts in athymic nude mice, the MTD of IT-101 was <15 mg/
kg qwk × 2 so that three weekly doses of IT-101 at 5 mg/kg (CPT
equivalents), three weekly doses of IT-101 at 10 mg/kg
(CPT equivalents), and a single dose of IT-101 at 15 mg/kg
(CPT equivalents) were planned for use in the present study. Ex-
cept for three treatment-related deaths in SCIDmice treated with
IT-101 (15 mg/kg, i.v., × 1), all animals tolerated the treatments
well. Treatments with three weekly doses of IT-101 at 5 mg/kg
and 10 mg/kg were well tolerated in all animals. Thus, the
MTD of i.v. IT-101 in tumor-bearing SCID mice was between
10 mg/kg qwk × 3 and 15 mg/kg single dose. As a result, we
dropped the IT-101 (15 mg/kg, i.v., × 1) arm from the dissemi-
nated models using NOD.scid/NCr mice. Therapy with i.p. CPT-
11 was generally well tolerated in both strains of animal. Mean
body weight loss of SCID mice and NOD.scid/NCr mice was
minimal.
In vivo efficacy of IT-101 against localized s.c. human lymphoma
xenograft models. In localized s.c. Daudi tumors, therapy was
Fig. 2. Administration of IT-101
(10 mg/kg, i.v., single dose) can
significantly inhibit tumor DNA Topo I
catalytic activity in lymphoma
xenografts as compared with CPT-11.
DNA relaxation assay was done with
nuclear extracts containing 0.5 μg total
protein, isolated from s.c. lymphoma
xenografts at four time points (before
dosing, and 2, 24, and 48 h after
dosing), as depicted. The mean
percentage of tumor DNA Topo I
catalytic activity inhibited by either
IT-101 or CPT-11 was calculated from
three or more separate experiments.
Error bars, SE.
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initiated 10 days after tumor cell inoculation. Forty-five SCID
mice with established localized s.c. tumor were allocated into
five different treatment groups of nine animals per group as de-
scribed earlier. The average tumor volume among all groups
was equally distributed. All untreated controls and animals
treated with CPT-11 developed progressive tumor growth with
an average tumor volume of >2,000 mm3 within 38 days and
59 days after tumor injection, respectively. In contrast, IT-101
(5 mg/kg, i.v., qwk × 3) and IT-101 (10 mg/kg, i.v., qwk × 3)
could significantly prolong the survival of the animals as
compared with those treated with CPT-11 (P < 0.0001 and
P < 0.0001, respectively; Fig. 3A). Five of nine mice (56%)
treated with IT-101 5 mg/kg and seven of nine mice (78%)
treated with IT-101 (10 mg/kg, i.v., qwk × 3) survived and
were pathologically confirmed disease-free after 126 days
posttreatment.
In s.c. Karpas 299 tumors, therapy was initiated four days af-
ter tumor cell inoculation. All untreated control mice developed
progressive tumor growth with an average tumor volume of
>2,000 mm3 within 25 days after tumor injection. As shown
in Fig. 3B, although the significant difference between the
groups treated with either IT-101 (5 mg/kg, i.v., qwk × 3) or
IT-101 (10 mg/kg, i.v., qwk × 3) was not observed, the animals
treated with IT-101 (10 mg/kg, i.v., qwk × 3) had significantly
longer survival than those treated with CPT-11 (P = 0.0072).
At the end of the study, 44% of animals treated with IT-101
(10 mg/kg, i.v., qwk × 3), 33% of animals treated with IT-
101 (5 mg/kg, i.v., qwk × 3), and 33% of animals treated
with CPT-11 achieved a pathologically confirmed disease-free
status.
The antilymphoma activity of IT-101 was also evaluated in
s.c. L540 tumors. In this model, therapy was initiated 16 days
after tumor cell inoculation. Tumors in all untreated control
mice grew rapidly with ulceration within 51 days after tumor
injection and were then sacrificed. Although a significantly lon-
ger survival could be observed in all CPT-11–treated mice as
compared with untreated controls (P = 0.018), all had progres-
sive tumor growth with ulceration within 79 days after tumor
implant. Consistent with the other s.c. xenografts, animals trea-
ted with IT-101 (5 mg/kg, i.v., qwk × 3) and IT-101 (10 mg/kg,
i.v., qwk × 3) had significantly longer survival than those trea-
ted with CPT-11 (P < 0.001 and P < 0.0001, respectively) as
shown in Fig. 3C. Seven of nine animals (78%) that received
either IT-101 (5 mg/kg, i.v., qwk × 3) or IT-101 (10 mg/kg, i.v.,
qwk × 3) were pathologically confirmed tumor free and
survived for at least 126 days after dosing.
In vivo efficacy of IT-101 against disseminated human lymphoma
xenograft models. Previous studies have shown that Daudi cells
and Karpas 299 cells injected i.v. into mice spread in a pattern
comparable with the dissemination of human lymphomas and
show preferential localization to the lymph nodes (32, 33).
We further evaluated the antilymphoma efficacy of IT-101 in
disseminated Daudi tumors in which the therapy was initiated
11 days after the tumor injection. All untreated controls died of
disseminated disease proceeding by progressive weight loss or
were sacrificed due to being moribund within 67 days after tu-
mor cell inoculation. In the same xenografts, 55.6% of animals
receiving IT-101 (10 mg/kg, i.v., qwk × 3) and 33.3% of ani-
mals receiving IT-101 (5 mg/kg, i.v., qwk × 3) could achieve
pathologic complete tumor response on day 125 posttreatment,
whereas none of animals receiving CPT-11 did so (Fig. 4A). In
addition, IT-101 (5 mg/kg, i.v., qwk × 3) and IT-101 (10 mg/kg,
i.v., qwk × 3) could significantly prolong the survival of animals
bearing disseminated Daudi+ ffLuc tumor when compared with
CPT-11 (P = 0.0002 and P < 0.0001, respectively), as shown in
Fig. 4B.
We also evaluated the efficacy of IT-101 in disseminated Kar-
pas 299+ ffLuc tumor in which the therapy was initiated eight
days after tumor cell injection. All untreated controls died of
disseminated disease with severe weight loss or were sacrificed
due to being moribund or reaching the predetermined end
point of ffLuc activity of >1010 p/s/cm2/sr within 29 days after
tumor cell inoculation (Fig. 5A). Although all of the animals
receiving therapy succumbed from disseminated disease by
day 83 after tumor cell injection, animals treated with IT-101
(10 mg/kg, i.v., qwk × 3) had significantly longer survival than
those treated with IT-101 (5 mg/kg, i.v., qwk × 3) and CPT-11
(P = 0.0009 and P = 0.0049, respectively) as shown in Fig. 5B.
Fig. 3. Administration of IT-101 (5 mg/kg, i.v., qwk × 3) and (10 mg/kg, i.v., qwk × 3) to animals bearing three distinct s.c. human lymphoma xenografts can
result in significant better survival as compared with CPT-11. Treatments were initiated at 10, 4, and 16 d after s.c. injection of Daudi, Karpas 299, and
L540 cells, respectively. Treatment arms included untreated control (▪), CPT-11 (100 mg/kg, i.p., qwk × 3) (⋄), IT-101 (5 mg/kg, i.v., qwk × 3) (○), and IT-101(10 mg/kg, i.v., qwk × 3) (x). The tumor burden was monitored longitudinally by physical measurements. Using the Kaplan-Meier method, the survival
curves were plotted for each treatment group and the log-rank test was used to compare the percent animal survival between treatment groups. In Daudi
and L540 tumors, a significant difference between the groups treated with either IT-101 (5 mg/kg, i.v., qwk × 3) or IT-101 (10 mg/kg, i.v., × 3) was not
observed. However, these two treatment groups achieved significantly better survival as compared with the groups treated with CPT-11 (P < 0.0001 and
P < 0.0001, respectively). In Karpas 299 tumors, no significant difference between the groups treated with either IT-101 (5 mg/kg, i.v., qwk × 3) or IT-101
(10 mg/kg, i.v., qwk × 3) was observed; but animals treated with IT-101 at (10 mg/kg, i.v., qwk × 3) had significantly better survival as compared with those
treated with CPT-11 (P = 0.0072). Points, mean survival.
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Discussion
In order to mitigate the disadvantages of CPT, i.e. high toxic-
ity and low clinical therapeutic efficacy, we recently attached it
to a hydrophilic β-cyclodextrin-based polymer known as IT-101
(26). IT-101 maintains CPT in its active lactone form. This
novel compound is too large to pass through normal vessel
walls and renal clearance is inhibited. Therefore, the compound
can achieve a long plasma half-life, permits a large amount of
the compound to reach the tumor site through an abnormally
leaky tumor vasculature, and accumulates in tumor tissue due
to a lack of effective lymphatic drainage (34–36). Based on our
previous study and unpublished data, the pharmacokinetics
and pharmacodynamics of IT-101 at various dose levels similar
to the ones explored here (0.9-9 mg/kg in rat, equivalent to 1.8-
18 mg/kg scaled allometrically to mouse) were previously stud-
ied in rats (26). Area under the curve and maximum plasma
concentration for both polymer-conjugated and unconjugated
CPT scaled linearly with dose and were similar when normal-
ized for the dose administered. Mean terminal half-life of con-
jugated CPT was 18 hours and independent of dose. These
results indicate a linear dose-plasma exposure correlation for
both conjugated and unconjugated CPT after administration
of IT-101. In animal models, not only is the mean plasma
elimination half-life for IT-101 (17-19 hours) significantly
longer than that of CPT (1.3 hours), but much higher average
24-hour total CPT levels are achieved in tumors after treat-
ment with IT-101 compared with those treated with CPT
alone (26). Because CPT is an S-phase-specific drug, an opti-
mal level of DNA Topo I inhibition is needed in which the
tumors are exposed to the compound for a prolonged period
of time. In addition, the lower level of freely circulating CPT
may reduce the TRT (26).
Our current data clearly show the advantage of this nanopar-
ticle technology, namely that IT-101 can provide superior antil-
ymphoma activity than that of CPT-11 against xenografts of
human lymphoma. In vitro, both IT-101 and CPT-11 caused
marked inhibition of growth of three distinct human lympho-
ma cell lines. Because the in vitro conditions lacked biodistribu-
tion and drug delivery variables, the observed cytotoxicity of
either IT-101 or CPT-11 was most likely due to its direct anti-
proliferative effect against these lymphoma cell lines tested. Be-
cause previous study has shown that the sensitivity of tumor
cells to DNA Topo I-targeted cytotoxic agents is related to the
level of DNA Topo I catalytic activity in the nucleus, we have
chosen the three distinct s.c. lymphoma xenografts that exert
a high level of DNA Topo I catalytic activity as the representa-
tives in our study (11). Our short-term in vivo studies showed
Fig. 4. Administration of IT-101 (5 mg/kg, i.v., qwk × 3) and IT-101 (10 mg/kg, i.v., qwk × 3) in disseminated human B-cell lymphoma xenograft-bearing
mice could result in significant better survival as compared with CPT-11. Treatments were initiated 11 d after tumor inoculation. The treatment arms included
untreated control (▪), CPT-11 (100 mg/kg, i.p., qwk × 3) (⋄), IT-101 (5 mg/kg, i.v., qwk × 3) (○), and IT-101 (10 mg/kg, i.v., qwk × 3) (x). The tumor burdenwas monitored longitudinally by quantification of tumor-derived ffLuc-activity. A, total photon flux normalized for exposure time and surface area and
expressed in units of p/s/cm2/sr for individual mice was graphed over time and serial pseudocolor images representing light intensity from Daudi+ ffLuc
in selected mice are shown. B, Kaplan-Meier survival curves were plotted for each treatment group. The log-rank test was used to compare the percent
animal survival between treatment groups. A significant difference between the groups treated with either IT-101 (5 mg/kg, i.v., qwk × 3) or IT-101 (10 mg/kg,
i.v., qwk × 3) was not observed; but these two treatment groups could significantly establish better survival as compared with the animals treated with
CPT-11 (P = 0.0002 and P < 0.0001, respectively). Points, mean survival.
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that IT-101 was able to significantly inhibit DNA Topo I cata-
lytic activity at 48 hours postadministration in Daudi and
Karpas 299 tumors as compared with CPT-11. Such an effect
results from the prolonged release kinetics of CPT from IT-
101 in tumor tissue, leading to a higher degree of cytotoxicity
as compared with CPT-11. This was consistent with our obser-
vation of higher levels of both IT-101 prodrug and free CPT ob-
served in tumors at 24 and 48 hours postadministration
compared with CPT-11 and its active metabolite SN-38. More-
over, the long-term therapeutic efficacy of IT-101 was clearly
superior to CPT-11. In localized s.c. xenografts, upon discontin-
uation of the IT-101 treatment, most of animals attained path-
ologic complete tumor response at the end of the study, in
agreement with the disseminated Daudi tumors treated with
IT-101 (10 mg/kg, i.v., qwk × 3). Among treatment groups,
IT-101 (10 mg/kg, i.v., qwk × 3) gave the best results in terms
of pathologic complete tumor response and survival benefit in
both s.c. and disseminated xenografts.
We also have shown that the MTD of IT-101 in SCID/NCr
(BALB/c background) and NOD.scid/NCr mice bearing human
lymphoma xenograft was less than that of athymic nude mice
(28). This result may be explained by the fact that the SCID/
NCr and NOD.scid/NCr mice are more immunocompromised
as compared with athymic nude mice. Recently, a novel SN-38-
incorporating polymeric micelle, NK012, has been developed
(37). This compound produced a much higher cytotoxic effect
against lung and colon cancer cell lines as compared with CPT-
11, mainly due to an enhancement and prolonged distribution
of free SN-38 in the tumor tissues. However, SN-38 is cross-re-
sistant with the first-line chemotherapeutic agents commonly
used in non-Hodgkin lymphoma such as doxorubicin and mi-
toxantrone (38, 39). Moreover, in a phase II study of CPT-11, a
good response (complete response and partial response) was
seen in only 0%, 38%, and 0% of patients with relapsed/refrac-
tory Hodgkin lymphoma, Burkitt lymphoma, and T-cell lym-
phoma (40). As a result, CPT-11 is not a good candidate in
treating relapsed/refractory non-Hodgkin lymphoma. Therefore,
the positive outcome of this study clearly shows the potential
clinical benefit of IT-101 and can help in the design of treat-
ment schedules in phase I clinical trials. IT-101 monotherapy
Fig. 5. IT-101 (10 mg/kg, i.v., qwk × 3) had superior antilymphoma activity as compared with IT-101 (5 mg/kg, i.v., qwk × 3) and CPT-11 in disseminated
human anaplastic large T-cell xenografts. NOD.scid/NCr mice were i.v. injected with ffLuc+ Karpas 299 cells to establish disseminated human anaplastic large
T-cell xenografts and treated with the indicated cytotoxic agent beginning 8 d later. Treatment arm included untreated control (▪), CPT-11 (100 mg/kg, i.p.,qwk × 3) (⋄), IT-101 (5 mg/kg, i.v., qwk × 3) (○), and IT-101 (10 mg/kg, i.v., qwk × 3) (x). The tumor burden was monitored longitudinally by quantification
of tumor-derived ffLuc-activity. A, total photon flux normalized for exposure time and surface area and expressed in p/s/cm2/sr for individual mice was
graphed over time and serial pseudocolor images representing light intensity from Karpas 299+ ffLuc in selected mice are shown. B, Kaplan-Meier survival
curves for each treatment group. The log-rank test was used to compare the percent animal survival among treatment groups. Animals treated with
IT-101 (10 mg/kg, i.v., qwk × 3) had significantly longer survival as compared with those treated with IT-101 (5 mg/kg, i.v., qwk × 3) and those treated with
CPT-11 (P = 0.0009, P = 0.0049, respectively). Points, mean survival.
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should be tested in patients with relapsed/refractory non-Hodg-
kin lymphoma. Many preclinical and clinical studies have
shown that a sequential administration of a DNA Topo I inhib-
itor followed by a DNA Topo II inhibitor exerts a synergistic
antilymphoma effect (41, 42). A recent study indicated that sin-
gle agent fluoroquinolone can inhibit both DNA Topo I and II
activities in eukaryotic cells; and in combination with either
CPT or etoposide, it led to a synergistic inhibition of DNA
Topo I or II activity, respectively (43). As a result, it would be
of value to further test an antilymphoma effect of IT-101 com-
bined with a DNA Topo II inhibitor or fluoroquinolone. The
dose-limiting toxicity of IT-101 is currently being determined
in ongoing phase I clinical trial at City of Hope Comprehensive
Cancer Center.
In conclusion, we have shown that IT-101 is able to control
and inhibit tumor growth both in vitro and in vivo, and prolong
survival of animals bearing multiple distinct human lymphoma
xenografts. This preclinical therapeutic efficacy of IT-101 sup-
ports its clinical evaluation in patients with non-Hodgkin lym-
phoma and Hodgkin lymphoma.
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